Shingrix is a recombinant protein subunit-based vaccine and is generally used in favour of an older shingles vaccine – Merck & Co's Zostavax – which is cased on a live, attenuated virus.
In our opinion, the five most important issues facing RSV F protein subunit-based vaccines in the next 5–10 years are the following: Determining whether RSV F protein subunit vaccines will be ...
These fusion proteins are the basis of many subunit vaccines, a type in which a part of the pathogen being vaccinated against is injected to prompt the body to efficiently raise an immune response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results